Nicholas Saraceno, Editor

The SSC strives to simply and add efficiencies to the scheduling technology used by the logistics sector.

Among its benefits, the fund will provide up to $8,000 in medication copayment or insurance premium assistance.

The transaction serves as way to expand customers’ access to products and capabilities.

The deal grows it pipeline, powered by panCAR programs in autoimmune disease and oncology.

With the acquisition, Merck’s US and Canada life science business aims to further increase its viral vector manufacturing capabilities.

The CDMO will run the active pharmaceutical ingredient pilot plant in Sandwich, UK, along with development laboratories.

The deal features felzartamab, an investigational anti-CD38 monoclonal antibody, whose clinical outcomes have shown potential to tackle various immune-mediated diseases.

The document reiterates the company’s commitment to ESG principles, including carbon neutrality by 2030.

The decision comes after success during formulation testing with convincing stability data.

The agreement is expected to focus on cell manufacturing processes, with potential for sharing tech with academia, startups.

The facility, company says, will be its first that covers end-to-end ADC production.

The company increases its selection of atopic dermatitis treatments in the process.

Leaders in the space discuss aspects of experimental drug support and more at this year’s US Pharma and Biotech Summit.

Chip Davis recaps the organization’s Distribution Management Conference and addresses distributors’ preparedness for DSCSA implementation.

The company has financially committed $13.1 million into the project.

The CDMO’s latest business venture reaffirms its commitment to the development of novel radiopharmaceuticals.

In an interview with Pharma Commerce Editor Nicholas Saraceno at LogiPharma Europe, Nick Porter, President, World Courier discusses mitigating supply chain risks, the future of artificial intelligence in pharma logistics, and more.

The company has financially committed more than $3.8 billion since the COVID-19 pandemic into keeping the medication and vaccine production process in France.

The development project adds an additional 157,500 square feet to the existing facility in the process.

A cohort study investigates how the use of a murine chimeric monoclonal antibody biosimilar—as opposed to the original biological drug—affects healthcare expenditures.

In an interview with Pharma Commerce Editor Nicholas Saraceno, Cathy O'Brien, VP of Sales, UPS Healthcare discusses current technology that the pharma industry is adopting when it comes to sustainability.

Parties sign co-exclusive licensing agreement, which includes a minority equity investment in Novavax, who will be receiving payments totaling as high as $1.2 billion when combining upfront payment and milestones.

The network now includes 30 pharmacies, who will help tackle accessibility.

In an interview with Pharma Commerce Editor Nicholas Saraceno, Cathy O'Brien, VP of Sales, UPS Healthcare discusses her masterclass on delivering agility in supply chains by building a multimodal cold chain network while also reducing risks at LogiPharma Europe 2024.

The CDMO’s Bedford, NH facility will welcome a new isolator filling line—along with twin lyophilizers—as part of a multi-year, $100 million capital investment project.

IQVIA report explores the latest spending tendencies in the United States, while providing additional clarity as to why COVID-19 vaccines and therapeutics continue to experience a decline in volume.

The latest accreditation further establishes the company’s reputation in the pharma and healthcare logistics space.

The acquisition, the parties say, will benefit pharma and biotech in the clinical and commercial stages.

In an interview with Pharma Commerce Editor Nicholas Saraceno, Martin Hawes, Global Head of Product Development, Tower Cold Chain offers insights on the future of cell & gene therapies when it comes to cold chain storage.

Collaboration will be oncology based—centered around allogeneic CAR-T cell therapy product candidates—and will provide Poseida with up to $550 million if certain milestones are met.